Inclusion Criteria:

- Patients who have received an allogeneic bone marrow or peripheral blood stem cell
transplant for AML, meeting one of the following: 1) AML arising from MDS or MDP
2)AML CR1 associated with high risk cytogenetics 3) AML transplanted in induction
failure or relapse 4) AML transplanted in second remission or beyond 5) AML in
patient 60 years or older

- Patients who have received an allogeneic bone marrow or peripheral blood stem cell
transplant for MDS-RAEB or CMML

- 18 years of age or older

- Donor is a related or unrelated donor who is at least 9/10 matched at HLA-A, B, C,
DRB1, and DQB1 by antigen level typing at class 1 and allele level typing at class II

- Recipients of myeloablative or reduced intensity conditioning transplants are
eligible

- Patient must have sufficient autologous tumor cells banked at DFCI (on companion
tissue banking protocol) for vaccine generation prior to transplantation

- No active GVHD requiring systemic corticosteroid therapy

- No conditions requiring systemic corticosteroid therapy greater than or equal to 20mg
methylprednisolone or equivalent

- No uncontrolled infection

- Adequate hematopoietic engraftment with ANC >500 off growth factor support, and
platelet >10k without transfusion

- No non-hematologic toxicity of CTC Grade 3 or greater

- ECOG Performance Status 0-2

Exclusion Criteria:

- Recipients of cord blood transplant

- Patients with uncontrolled CNS disease

- Patients with relapsed/persistent disease after transplant who are expected to
require rapid withdrawal of immune suppression, cytoreductive therapy, or have a life
expectancy of < 3 months

- Concurrent participation in other transplant clinical trials where GVHD and/or
disease relapse are primary endpoints

- Patients deemed medically or psychologically unfit by treating physician or study
investigator